Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

The aldosterone antagonist and facultative diuretic eplerenone: a critical review.

Reyes AJ, Leary WP, Crippa G, Maranhão MF, Hernández-Hernández R.

Eur J Intern Med. 2005 Feb;16(1):3-11.

PMID:
15733814
2.
3.

Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.

Dieterich HA, Wendt C, Saborowski F.

Fiziol Cheloveka. 2005 Nov-Dec;31(6):97-105. Review.

PMID:
16366159
4.

Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?

Jewell CW, Watson LE, Mock J, Dostal DE.

Cardiovasc Hematol Agents Med Chem. 2006 Apr;4(2):129-53. Review.

PMID:
16611048
5.

Aldosterone antagonists in the treatment of heart failure.

Marcy TR, Ripley TL.

Am J Health Syst Pharm. 2006 Jan 1;63(1):49-58.

PMID:
16373465
6.
7.

The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Thomas GN, Chan P, Tomlinson B.

Drugs Aging. 2006;23(2):131-55. Review.

PMID:
16536636
8.

Aldosterone and volume management in hypertensive heart disease.

Sica DA.

Semin Nephrol. 2014 May;34(3):323-32. doi: 10.1016/j.semnephrol.2014.04.007. Epub 2014 Apr 18. Review.

PMID:
25016402
9.

The future of antihypertensive treatment.

Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):121-34. Review.

PMID:
17414579
10.

[The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design].

Cacciatore G, Boccanelli A, Mureddu GF, Maggioni AP, Latini R, Masson S, de Simone G; Investigatori dell' Area In-CHF.

Ital Heart J. 2005 May;6 Suppl 1:66S-74S. Review. Italian.

PMID:
15945301
11.
12.

The 45-year story of the development of an anti-aldosterone more specific than spironolactone.

Ménard J.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.

PMID:
15134800
13.

Update of diuretics in the treatment of hypertension.

Padilla MC, Armas-Hernández MJ, Hernández RH, Israili ZH, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):154-60. Review.

PMID:
17414583
14.

Aldosterone antagonists in the treatment and prevention of heart failure.

Boxer RS, Dunlap ME.

Curr Treat Options Cardiovasc Med. 2005 Dec;7(6):431-6.

PMID:
16283969
15.

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

Gross E, Rothstein M, Dombek S, Juknis HI.

Am J Kidney Dis. 2005 Jul;46(1):94-101.

PMID:
15983962
16.

Are we misunderstanding beta-blockers.

Cruickshank JM.

Int J Cardiol. 2007 Aug 9;120(1):10-27. Epub 2007 Apr 12. Review.

PMID:
17433471
17.

Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?

Bansal S, Lindenfeld J, Schrier RW.

Circ Heart Fail. 2009 Jul;2(4):370-6. doi: 10.1161/CIRCHEARTFAILURE.108.821199. Review.

18.

Aldosterone receptor antagonism in heart failure.

Jennings DL, Kalus JS, O'Dell KM.

Pharmacotherapy. 2005 Aug;25(8):1126-33. Review.

PMID:
16207104
19.

Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone.

Delyani JA.

Expert Opin Investig Drugs. 1998 May;7(5):753-9.

PMID:
15991966
20.

Supplemental Content

Support Center